9 Best Small Cap Stocks with Biggest Upside Potential

4. Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)

Market Capitalization as of August 15: $1.36 billion

Number of Hedge Fund Holders: 51

Average Upside Potential as of August 15: 122.36%

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best small cap stocks with biggest upside potential. On August 5, BTIG analyst Justin Zelin raised the firm’s price target on Syndax to $56 from $43, while maintaining a Buy rating on the shares. The company delivered strong Q2 2025 results, with Revuforj and Niktimvo posting breakout commercial performance that exceeded internal and external expectations for Q2 and surpassed benchmarks set by precedent AML launches.

The company’s total revenue for the quarter was $38 million. This was comprised of $28.6 million in net product revenue from Revuforj, which was a 43% sequential increase, and $9.4 million in collaboration revenue from Niktimvo. Niktimvo, which is co-commercialized with Incyte, generated $36.2 million in net revenue during its first full quarter since its late January 2025 launch.

Syndax is advancing its pipeline and regulatory milestones. The US FDA granted Priority Review for the supplemental New Drug Application/sNDA for Revuforj to treat relapsed or refractory (R/R) mutant NPM1 acute myeloid leukemia/AML with a target action date of October 25 this year. If approved, it would be the first therapy for this indication. Additionally, the company is conducting multiple trials for both Revuforj and Niktimvo in new indications and in combination with other therapies.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer.